 |
Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease
Enrolment in XanaCIDD phase 2a trial of cognitive impairment and depression has surpassed 90%
SYDNEY, April 15, 2024 /PRNewswire/ -- Actinogen Medical...
Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...
Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...
Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...